Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.
In the paper published in EClinical Medicine by The Lancet, the research team examined lesions of the retina, the inner-most, light-sensitive layer of the eye, to determine if… read more.
Women who currently use hormonal contraceptives face more than a 2-fold higher risk of developing glaucoma, according to an analysis of electronic medical records for women aged 15-45… read more.
A simple eye exam combined with powerful artificial intelligence (AI) machine learning technology could provide early detection of Parkinson’s disease, according to research being presented at the annual… read more.
by Bruce Sylvester: One dosing with methylene blue appears to increase MRI-based response in brain areas that control short-term memory and attention, researchers reported on June 28 in… read more.
by Bruce Sylvester: Investigators from a phase l/II clinical trial report that high-dose atorvastatin treatment of patients with the dry form of age-related macular degeneration (AMD) resulted in… read more.
by Bruce Sylvester: Phenytoin, a drug used to prevent seizures in epilepsy, appears to help protect the eyesight of persons with multiple sclerosis (MS). Researchers reported this finding… read more.
by Bruce Sylvester: Ranibizumab (Lucentis®) therapy appears to have efficacy in reversing diabetes-related vision loss in some populations, researchers reported online on Feb. 19 in the journal Opthalmology.
Sustained release treatment option could soon be available for diabetic patients in 28 countries of the European Union.
by Bruce Sylvester – Less than half of Americans with eye damage caused by diabetes are aware of the connection between diabetes and visual impairment, researchers reported online… read more.
Investigators reported on Oct. 22 in the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) that treatment with adalimumab may be effective for patients with… read more.
Patients who are otherwise completely unable to communicate can answer yes or no questions within seconds with the help of a simple system—consisting of just a laptop and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
